<h2>关键点</h2>
<ul>
<li>CRISPR Therapeutics 作为商业阶段的领导者，拥有市场上已获批准的基因编辑疗法，具备先发优势。</li>
<li>Editas Medicine 正在战略性地转向体内基因编辑，以针对更广泛的严重遗传疾病。</li>
<li>权衡这些基因医学先驱的利弊，可以洞察哪一家公司更适合投资。</li>
<li>我们更看好的 10 只股票 ›</li>
</ul>
<p>基因编辑技术已从科幻走向临床现实，迫使投资者在商业领导者和早期创新者之间做出选择。在 <strong>CRISPR Therapeutics AG</strong>(NASDAQ:CRSP) 和 <strong>Editas Medicine</strong>(NASDAQ:EDIT) 之间的决策需要权衡当前销售与长期潜力。</p>
<p>CRISPR Therapeutics 通过一项重要合作专注于高知名度的血红蛋白病治疗，而 Editas 则战略性地瞄准体内基因编辑。两者代表了基因医学的前沿，但在 2026 年为个人投资者提供了截然不同的财务状况和风险水平。</p>
<h2>支持 CRISPR Therapeutics 的理由</h2>
<p>CRISPR Therapeutics 是一家基因编辑生物制药公司，专注于开发变革性药物，如用于镰状细胞病的 CASGEVY。它在血红蛋白病和肿瘤学市场中运营，同时将其研发业务集中在马萨诸塞州。由于 <strong>Vertex Pharmaceuticals</strong> 负责 CASGEVY 的所有商业化活动，该公司的收入完全依赖于这一单一合作伙伴。客户集中度的这种情况为业务增加了一层风险。</p>
<p>在 2025 财年，来自补助的收入总计 350 万美元，而前一年来自 Vertex 的预付款为 3500 万美元。这导致净亏损为 5.816 亿美元，公司报告该期间的净利润率为负 16570%。年同比趋势反映出其向商业化主导疗法的转变，而不是依赖一次性里程碑付款。</p>
<p>截至 2025 年 12 月的资产负债表，债务与股本比率约为 0.2 倍。该比率比较总债务与股东权益的价值，表明杠杆水平较为保守。流动比率，即衡量公司用现金等资产覆盖短期债务的能力，接近 13.3 倍。该财年的自由现金流为负 3.459 亿美元，代表了支持持续研究和商业化所消耗的现金。</p>
<h2>支持 Editas Medicine 的理由</h2>
<p>Editas Medicine 专注于将 CRISPR 技术转化为体内药物，这些药物直接输送到患者体内。该公司在 生物科技股票 市场中运营，并依赖与 <strong>Bristol Myers Squibb</strong> 和 Vertex Pharmaceuticals 的合作进行融资。由于这些许可证代表了其唯一的承诺资金来源，这种收入来源的高度集中增加了投资者的风险。</p>
<p>在 2025 财年，收入为 4050 万美元，同比增长约 25.4%。尽管实现了增长，公司仍报告净亏损为 1.601 亿美元，净利润率为负 395%。这一数字突显了在复杂基因疗法开发过程中，达到商业市场之前所需的高成本。</p>
<p>该公司在 2025 年 12 月结束时的债务与股本比率约为 2.8 倍。该比率比较总债务与股东权益的价值。其流动比率约为 3.5 倍，表明其保持足够的流动资产以满足即时财务义务。该财年的自由现金流为负 1.658 亿美元，这是在支出物理设备后的运营净现金使用。</p>
<h2>风险概况比较</h2>
<p>CRISPR Therapeutics 在其主要产品的商业成功上严重依赖 Vertex Pharmaceuticals，这限制了其对收入时机的控制。该公司还面临持续的法律挑战，包括 2025 年的专利侵权诉讼。此外，其基因编辑平台的新颖性引入了临床暂停或监管拒绝的风险，尤其是在出现安全问题时。</p>
<p>Editas Medicine 严重依赖于单一的临床前候选药物，这意味着早期测试中的任何挫折都可能严重影响其估值。它还面临来自更大公司的激烈竞争，尤其是在拥挤的细胞治疗领域。此外，缺乏内部制造设施迫使公司依赖第三方供应商，可能导致供应链中断。</p>
<h2>估值比较</h2>
<p>根据其 市销率，Editas Medicine 看起来更便宜，该比率比较市场价值与销售额，而 CRISPR Therapeutics 的 前瞻市盈率 则衡量价格与未来收益预期的关系。</p>
<table>
<thead>
<tr>
<th>指标</th>
<th>CRISPR Therapeutics AG</th>
<th>Editas Medicine</th>
<th>行业基准</th>
</tr>
</thead>
<tbody>
<tr>
<td>前瞻市盈率</td>
<td>23.4 倍</td>
<td>不适用</td>
<td>27.5 倍</td>
</tr>
<tr>
<td>市销率</td>
<td>5190 倍</td>
<td>8 倍</td>
<td>不适用</td>
</tr>
</tbody>
</table>
<p>行业基准使用的是 SPDR XLV 行业 ETF。估值指标来源于 Financial Modeling Prep (FMP)，可能与其他数据提供商有所不同。</p>
<h2>我在 2026 年会买哪只股票？</h2>
<p>由于 CRISPR Therapeutics 和 Editas Medicine 都是早期阶段的医疗公司，因此对投资者来说风险很大。在这一点上，决定投资哪只基因编辑股票取决于个人投资者的风险承受能力。</p>
<p>CRISPR Therapeutics 的 CASGEVY 解决方案是首个获得 FDA 批准的 CRISPR 治疗。这使其在 Editas 之前占据了优势，后者尚未获得 FDA 对其产品的批准。没有 FDA 的认可，销售无法进行。</p>
<p>此外，CRISPR Therapeutics 在第一季度末报告现金为 4.233 亿美元，总资产为 27 亿美元。其 13.3 倍的流动比率很强，能够使公司达到其疗法开始产生销售的阶段。</p>
<p>Editas 具有更大的股价上涨潜力。其远低于的市销率表明其股票估值合理，而 CRISPR Therapeutics 则显得过于昂贵。尽管如此，其资产负债表并不如前者强劲，现金为 1.466 亿美元，总资产为 1.865 亿美元，而总负债为 1.592 亿美元。该公司于 5 月 26 日宣布发行更多股票以筹集资金，这稀释了股东权益。</p>
<p>在审视这两家基因治疗公司的利弊后，我的选择是 CRISPR Therapeutics，因为它在财务上处于更强的位置，并且在将其解决方案推向市场方面进展更快。</p>
<h2>你现在应该购买 CRISPR Therapeutics 的股票吗？</h2>
<p>在你购买 CRISPR Therapeutics 的股票之前，请考虑以下几点：</p>
<p><em>Motley Fool Stock Advisor</em> 分析团队刚刚确定了他们认为的 <strong>10 只最佳股票</strong> 供投资者现在购买……而 CRISPR Therapeutics 并不在其中。入选的 10 只股票在未来几年可能会产生巨大的回报。</p>
<p>考虑一下 <strong>Netflix</strong> 在 2004 年 12 月 17 日上榜时……如果你在我们推荐时投资了 1,000 美元，<strong>你现在将拥有 463,900 美元</strong>！* 或者 <strong>Nvidia</strong> 在 2005 年 4 月 15 日上榜时……如果你在我们推荐时投资了 1,000 美元，<strong>你现在将拥有 1,294,401 美元</strong>！*</p>
<p>现在值得注意的是 <em>Stock Advisor</em> 的总平均回报率为 978%——相比之下，标准普尔 500 指数的回报率为 211%。<strong>不要错过最新的前 10 名股票列表，加入由个人投资者为个人投资者建立的投资社区，获取 <em>Stock Advisor</em> 的最新信息。</strong></p>
<p>查看 10 只股票 »</p>
<p><em>*Stock Advisor 的回报截至 2026 年 5 月 31 日。</em></p>
<p><em>Robert Izquierdo 在提到的任何股票中均没有持仓。Motley Fool 持有并推荐 Bristol Myers Squibb、CRISPR Therapeutics 和 Vertex Pharmaceuticals。Motley Fool 推荐 Editas Medicine。Motley Fool 有 披露政策.</em></p>
<p>此处表达的观点和意见仅代表作者的观点，并不一定反映 Nasdaq, Inc. 的观点。</p>

CRISPR治疗

EDIT

生物科技 ETF - VanEck Vectors

<p>本文比较了 CRISPR 治疗和 Editas Medicine 作为 2026 年的投资选项。CRISPR 凭借获得批准的疗法 CASGEVY 拥有先发优势，但面临高额亏损和对 Vertex 的依赖。Editas 则转向体内编辑，显示出收入增长，但净亏损显著且杠杆率较高。虽然 CRISPR 提供了商业现实，但 Editas 的估值指标较低。选择取决于投资者对商业化产品与早期创新的风险承受能力</p>

<h2>Key Points</h2>
<div class="lb-trans"><h2>关键点</h2>
</div><ul>
<li>CRISPR Therapeutics holds a first-mover advantage as a commercial-stage leader with an approved gene-editing therapy on the market.</li>
<li>Editas Medicine is strategically pivoting toward in vivo gene editing to target a broader range of serious genetic diseases.</li>
<li>Weighing the pros and cons of these genomic medicine pioneers provides insight into which makes a better investment.</li>
<li>10 stocks we like better than CRISPR Therapeutics ›</li>
</ul>
<div class="lb-trans"><ul>
<li>CRISPR Therapeutics 作为商业阶段的领导者，拥有市场上已获批准的基因编辑疗法，具备先发优势。</li>
<li>Editas Medicine 正在战略性地转向体内基因编辑，以针对更广泛的严重遗传疾病。</li>
<li>权衡这些基因医学先驱的利弊，可以洞察哪一家公司更适合投资。</li>
<li>我们更看好的 10 只股票 ›</li>
</ul>
</div><p>Gene-editing technology has moved from science fiction to clinical reality, forcing investors to choose between commercial leaders and early-stage innovators. Deciding between <strong>CRISPR Therapeutics AG</strong>(NASDAQ:CRSP) and <strong>Editas Medicine</strong>(NASDAQ:EDIT) requires weighing current sales against long-term potential.</p>
<div class="lb-trans"><p>基因编辑技术已从科幻走向临床现实，迫使投资者在商业领导者和早期创新者之间做出选择。在 <strong>CRISPR Therapeutics AG</strong>(NASDAQ:CRSP) 和 <strong>Editas Medicine</strong>(NASDAQ:EDIT) 之间的决策需要权衡当前销售与长期潜力。</p>
</div><p>CRISPR Therapeutics focuses on high-profile hemoglobinopathy treatments through a major partnership, while Editas is strategically targeting in vivo gene editing. Both represent the cutting edge of genomic medicine, but they offer vastly different financial profiles and risk levels for individual investors in 2026.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 通过一项重要合作专注于高知名度的血红蛋白病治疗，而 Editas 则战略性地瞄准体内基因编辑。两者代表了基因医学的前沿，但在 2026 年为个人投资者提供了截然不同的财务状况和风险水平。</p>
</div><h2>The case for CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>支持 CRISPR Therapeutics 的理由</h2>
</div><p>CRISPR Therapeutics is a gene-editing biopharmaceutical company focused on developing transformative medicines like CASGEVY for sickle cell disease. It serves markets in hemoglobinopathies and oncology while centering its research and development operations in Massachusetts. Because <strong>Vertex Pharmaceuticals</strong> handles all commercialization activities for CASGEVY, the company's revenue is entirely tied to this single partner. Customer concentration like this adds a layer of risk to the business.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 是一家基因编辑生物制药公司，专注于开发变革性药物，如用于镰状细胞病的 CASGEVY。它在血红蛋白病和肿瘤学市场中运营，同时将其研发业务集中在马萨诸塞州。由于 <strong>Vertex Pharmaceuticals</strong> 负责 CASGEVY 的所有商业化活动，该公司的收入完全依赖于这一单一合作伙伴。客户集中度的这种情况为业务增加了一层风险。</p>
</div><p>In its 2025 fiscal year, revenue generated from grants totaled $3.5 million, compared to the $35 million in upfront payments provided by Vertex in the prior year. This contributed to a net loss of $581.6 million, and the company reported a net margin of negative 16,570% for the period. The year-over-year trend reflects the transition toward commercializing its lead therapy rather than relying on one-time milestone payments.</p>
<div class="lb-trans"><p>在 2025 财年，来自补助的收入总计 350 万美元，而前一年来自 Vertex 的预付款为 3500 万美元。这导致净亏损为 5.816 亿美元，公司报告该期间的净利润率为负 16570%。年同比趋势反映出其向商业化主导疗法的转变，而不是依赖一次性里程碑付款。</p>
</div><p>As of the December 2025 balance sheet, the debt-to-equity ratio was approximately 0.2x. This ratio compares total debt to the value of shareholder equity, indicating a conservative amount of leverage. The current ratio, which measures a company's ability to cover short-term debts with assets like cash, was nearly 13.3x. Free cash flow for the year was negative $345.9 million, representing the cash burned to support ongoing research and commercialization.</p>
<div class="lb-trans"><p>截至 2025 年 12 月的资产负债表，债务与股本比率约为 0.2 倍。该比率比较总债务与股东权益的价值，表明杠杆水平较为保守。流动比率，即衡量公司用现金等资产覆盖短期债务的能力，接近 13.3 倍。该财年的自由现金流为负 3.459 亿美元，代表了支持持续研究和商业化所消耗的现金。</p>
</div><h2>The case for Editas Medicine</h2>
<div class="lb-trans"><h2>支持 Editas Medicine 的理由</h2>
</div><p>Editas Medicine is focused on translating CRISPR technology into in vivo medicines, which are therapies delivered directly into the patient's body. The company operates within the market for biotech stocks and relies on collaborations with <strong>Bristol Myers Squibb</strong> and Vertex Pharmaceuticals for funding. Because these licenses represent its only committed potential source of funds, this high concentration of revenue sources increases risk for investors.</p>
<div class="lb-trans"><p>Editas Medicine 专注于将 CRISPR 技术转化为体内药物，这些药物直接输送到患者体内。该公司在 生物科技股票 市场中运营，并依赖与 <strong>Bristol Myers Squibb</strong> 和 Vertex Pharmaceuticals 的合作进行融资。由于这些许可证代表了其唯一的承诺资金来源，这种收入来源的高度集中增加了投资者的风险。</p>
</div><p>During the 2025 fiscal year, revenue was $40.5 million, representing growth of approximately 25.4% compared to the previous year. Despite this growth, the company reported a net loss of $160.1 million and a net margin of negative 395%. This figure highlights the high costs associated with developing complex genomic therapies before they reach the commercial market.</p>
<div class="lb-trans"><p>在 2025 财年，收入为 4050 万美元，同比增长约 25.4%。尽管实现了增长，公司仍报告净亏损为 1.601 亿美元，净利润率为负 395%。这一数字突显了在复杂基因疗法开发过程中，达到商业市场之前所需的高成本。</p>
</div><p>The company ended the December 2025 period with a debt-to-equity ratio of approximately 2.8x. This ratio compares total debt to the value of shareholder equity. Its current ratio was roughly 3.5x, suggesting it maintains enough liquid assets to meet its immediate financial obligations. Free cash flow for the fiscal year was negative $165.8 million, which is the net cash used in operations after spending on physical equipment.</p>
<div class="lb-trans"><p>该公司在 2025 年 12 月结束时的债务与股本比率约为 2.8 倍。该比率比较总债务与股东权益的价值。其流动比率约为 3.5 倍，表明其保持足够的流动资产以满足即时财务义务。该财年的自由现金流为负 1.658 亿美元，这是在支出物理设备后的运营净现金使用。</p>
</div><h2>Risk profile comparison</h2>
<div class="lb-trans"><h2>风险概况比较</h2>
</div><p>CRISPR Therapeutics faces significant dependency on Vertex Pharmaceuticals for the commercial success of its lead product, which limits its control over the timing of revenue. The company also deals with ongoing legal challenges, including a 2025 patent infringement lawsuit. Furthermore, the novel nature of its gene-editing platform introduces risks of clinical holds or regulatory denials if safety issues arise.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 在其主要产品的商业成功上严重依赖 Vertex Pharmaceuticals，这限制了其对收入时机的控制。该公司还面临持续的法律挑战，包括 2025 年的专利侵权诉讼。此外，其基因编辑平台的新颖性引入了临床暂停或监管拒绝的风险，尤其是在出现安全问题时。</p>
</div><p>Editas Medicine is heavily reliant on a single preclinical candidate, meaning any setbacks in early testing could severely impact its valuation. It also faces intense competition from larger firms in the crowded cell therapy space. Additionally, a lack of internal manufacturing facilities forces the company to depend on third-party providers, creating potential for supply chain disruptions.</p>
<div class="lb-trans"><p>Editas Medicine 严重依赖于单一的临床前候选药物，这意味着早期测试中的任何挫折都可能严重影响其估值。它还面临来自更大公司的激烈竞争，尤其是在拥挤的细胞治疗领域。此外，缺乏内部制造设施迫使公司依赖第三方供应商，可能导致供应链中断。</p>
</div><h2>Valuation comparison</h2>
<div class="lb-trans"><h2>估值比较</h2>
</div><p>Editas Medicine looks cheaper based on its P/S ratio, which compares market value to sales, while CRISPR Therapeutics has a Forward P/E measuring price against future earnings estimates.</p>
<div class="lb-trans"><p>根据其 市销率，Editas Medicine 看起来更便宜，该比率比较市场价值与销售额，而 CRISPR Therapeutics 的 前瞻市盈率 则衡量价格与未来收益预期的关系。</p>
</div><table>
<thead>
<tr>
<th>Metric</th>
<th>CRISPR Therapeutics AG</th>
<th>Editas Medicine</th>
<th>Sector Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forward P/E</td>
<td>23.4x</td>
<td>n/a</td>
<td>27.5x</td>
</tr>
<tr>
<td>P/S ratio</td>
<td>5,190x</td>
<td>8x</td>
<td>n/a</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>指标</th>
<th>CRISPR Therapeutics AG</th>
<th>Editas Medicine</th>
<th>行业基准</th>
</tr>
</thead>
<tbody>
<tr>
<td>前瞻市盈率</td>
<td>23.4 倍</td>
<td>不适用</td>
<td>27.5 倍</td>
</tr>
<tr>
<td>市销率</td>
<td>5190 倍</td>
<td>8 倍</td>
<td>不适用</td>
</tr>
</tbody>
</table>
</div><p><em>Sector benchmark uses the SPDR XLV sector ETF. Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.</em></p>
<div class="lb-trans"><p>行业基准使用的是 SPDR XLV 行业 ETF。估值指标来源于 Financial Modeling Prep (FMP)，可能与其他数据提供商有所不同。</p>
</div><h2>Which stock would I buy in 2026?</h2>
<div class="lb-trans"><h2>我在 2026 年会买哪只股票？</h2>
</div><p>Because CRISPR Therapeutics and Editas Medicine are both early-stage healthcare companies, they hold a lot of risk for investors. At this point, deciding which gene editing stock to invest in comes down to the individual investor’s risk tolerance.</p>
<div class="lb-trans"><p>由于 CRISPR Therapeutics 和 Editas Medicine 都是早期阶段的医疗公司，因此对投资者来说风险很大。在这一点上，决定投资哪只基因编辑股票取决于个人投资者的风险承受能力。</p>
</div><p>CRISPR Therapeutics’ CASGEVY solution was the the first-ever FDA-approved CRISPR therapy. This gives it a leg up on Editas, which has yet to achieve FDA approval on its offerings. Without the FDA’s blessing, no sales can happen.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 的 CASGEVY 解决方案是首个获得 FDA 批准的 CRISPR 治疗。这使其在 Editas 之前占据了优势，后者尚未获得 FDA 对其产品的批准。没有 FDA 的认可，销售无法进行。</p>
</div><p>Moreover, CRISPR Therapeutics reported cash of $423.3 million at the end of the first quarter and $2.7 billion in total assets. Its 13.3x current ratio is strong, and positions the company to get to the point where its therapies can begin to collect sales.</p>
<div class="lb-trans"><p>此外，CRISPR Therapeutics 在第一季度末报告现金为 4.233 亿美元，总资产为 27 亿美元。其 13.3 倍的流动比率很强，能够使公司达到其疗法开始产生销售的阶段。</p>
</div><p>Editas has the potential for greater share price upside. Its far lower P/S ratio indicates its stock valuation is reasonable, while CRISPR Therapeutics is far too expensive. That said, its balance sheet is not as strong with cash of $146.6 million and total assets of $186.5 million compared to total liabilities of $159.2 million. The company announced the issuance of more stock on May 26 as a way to raise funds, which dilutes shareholder equity.</p>
<div class="lb-trans"><p>Editas 具有更大的股价上涨潜力。其远低于的市销率表明其股票估值合理，而 CRISPR Therapeutics 则显得过于昂贵。尽管如此，其资产负债表并不如前者强劲，现金为 1.466 亿美元，总资产为 1.865 亿美元，而总负债为 1.592 亿美元。该公司于 5 月 26 日宣布发行更多股票以筹集资金，这稀释了股东权益。</p>
</div><p>Examining the pros and cons of these two gene therapy companies, my pick would be CRISPR Therapeutics because it is in a financially stronger position, and further along in getting its solutions to market.</p>
<div class="lb-trans"><p>在审视这两家基因治疗公司的利弊后，我的选择是 CRISPR Therapeutics，因为它在财务上处于更强的位置，并且在将其解决方案推向市场方面进展更快。</p>
</div><h2>Should you buy stock in CRISPR Therapeutics right now?</h2>
<div class="lb-trans"><h2>你现在应该购买 CRISPR Therapeutics 的股票吗？</h2>
</div><p>Before you buy stock in CRISPR Therapeutics, consider this:</p>
<div class="lb-trans"><p>在你购买 CRISPR Therapeutics 的股票之前，请考虑以下几点：</p>
</div><p>The <em>Motley Fool Stock Advisor</em> analyst team just identified what they believe are the <strong>10 best stocks</strong> for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.</p>
<div class="lb-trans"><p><em>Motley Fool Stock Advisor</em> 分析团队刚刚确定了他们认为的 <strong>10 只最佳股票</strong> 供投资者现在购买……而 CRISPR Therapeutics 并不在其中。入选的 10 只股票在未来几年可能会产生巨大的回报。</p>
</div><p>Consider when <strong>Netflix</strong> made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, <strong>you’d have $463,900</strong>!* Or when <strong>Nvidia</strong> made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, <strong>you’d have $1,294,401</strong>!*</p>
<div class="lb-trans"><p>考虑一下 <strong>Netflix</strong> 在 2004 年 12 月 17 日上榜时……如果你在我们推荐时投资了 1,000 美元，<strong>你现在将拥有 463,900 美元</strong>！* 或者 <strong>Nvidia</strong> 在 2005 年 4 月 15 日上榜时……如果你在我们推荐时投资了 1,000 美元，<strong>你现在将拥有 1,294,401 美元</strong>！*</p>
</div><p>Now, it’s worth noting <em>Stock Advisor’s</em> total average return is 978% — a market-crushing outperformance compared to 211% for the S&amp;P 500. <strong>Don't miss the latest top 10 list, available with <em>Stock Advisor</em>, and join an investing community built by individual investors for individual investors.</strong></p>
<div class="lb-trans"><p>现在值得注意的是 <em>Stock Advisor</em> 的总平均回报率为 978%——相比之下，标准普尔 500 指数的回报率为 211%。<strong>不要错过最新的前 10 名股票列表，加入由个人投资者为个人投资者建立的投资社区，获取 <em>Stock Advisor</em> 的最新信息。</strong></p>
</div><p>See the 10 stocks »</p>
<div class="lb-trans"><p>查看 10 只股票 »</p>
</div><p><em>*Stock Advisor returns as of May 31, 2026.</em></p>
<div class="lb-trans"><p><em>*Stock Advisor 的回报截至 2026 年 5 月 31 日。</em></p>
</div><p><em>Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb, CRISPR Therapeutics, and Vertex Pharmaceuticals. The Motley Fool recommends Editas Medicine. The Motley Fool has a disclosure policy.</em></p>
<div class="lb-trans"><p><em>Robert Izquierdo 在提到的任何股票中均没有持仓。Motley Fool 持有并推荐 Bristol Myers Squibb、CRISPR Therapeutics 和 Vertex Pharmaceuticals。Motley Fool 推荐 Editas Medicine。Motley Fool 有 披露政策.</em></p>
</div><p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
<div class="lb-trans"><p>此处表达的观点和意见仅代表作者的观点，并不一定反映 Nasdaq, Inc. 的观点。</p>
</div>

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

nasdaq

Editas Medicine

动态生物技术与基因组 ETF - Invesco

基因免疫&健康关怀 ETF - iShares

标普生物技术 3 倍做多 - Direxion

Wisdomtree BioRevolution Fund ETF

标普生物技术 3 倍做空 - Direxion

医疗业 ETF - Vanguard

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

美国制药 ETF - iShares

创新 ETF - ARK

医疗业 ETF - SPDR

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

Invesco Nasdaq Biotechnology ETF

医药突破 ETF - ALPS

福泰制药

百时美施贵宝

Bristol-Myers Squibb Company

CRISPR 治疗与 Editas Medicine：哪只基因编辑股票在 2026 年更值得买入？